UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 13, 2007
APEX
BIOVENTURES ACQUISITION CORPORATION
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
6770
|
|
20-4997725
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
18
Farm Lane
Hillsborough,
California 94010
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (650)
344-3029
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
ITEM
8.01 OTHER EVENTS.
On
June
13,
2007,
Apex
Bioventures Acquisition Corporation
(the
“Company”)
consummated the initial public offering (the “IPO”)
of
7,500,000 units (the “Units”)
and
the concurrent sale of 1,125,000 units in connection with the exercise by the
underwriters of their over-allotment option (the “Over-Allotment
Option”).
Each
Unit consists of one share of the Company's common stock, par value $0.0001
per
share (the “Common
Stock”)
and
one warrant to purchase one share of Common Stock (the “Warrants”).
The
Units were sold at an offering price of $8.00 per Unit. Immediately prior to
the
consummation of the IPO, the Company completed a private placement with its
officers, directors and existing stockholders of 1,800,000 warrants at a
purchase price of $1.00 per warrant. The warrants sold in the private placement
were identical to the warrants included in the Units, except that such warrants
are non-redeemable and may be exercisable on a cashless basis. The IPO,
including the exercise of the Over-Allotment Option and the private placement
of
warrants, generated gross proceeds of $70,800,000. Of this amount, $67,330,000
is being held in trust, including the deferred underwriting discounts.
Audited
financial statements as of June 13, 2007 reflecting receipt of the proceeds
upon
consummation of the IPO have been issued by the Company and are included as
Exhibit 99.1 to this Current Report on Form 8-K.
In
addition, the Code of Conduct and Ethics of the Company is hereby included
as
Exhibit 99.3 to this Current Report on Form 8-K.
ITEM
9.01 FINANCIAL STATEMENTS AND EXHIBITS
|
99.1
|
Audited
Financial Statements
|
|
99.2
|
Press
Release dated June 13, 2007
|
|
99.3
|
Code
of Conduct and Ethics
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
APEX
BIOVENTURES ACQUISITION CORPORATION
|
|
|
|
|
|
|
|
|
/s/
Darrell J. Elliott
|
|
|
Darrell
J. Elliott
|
|
|
Chairman
and Chief Executive Officer
|
|
Dated
June 19, 2007
EXHIBIT
INDEX
Exhibit
Number
|
Description
|
|
99.1
|
Audited
Financial Statements
|
|
99.2
|
Press
Release dated June 13, 2007
|
|
99.3
|
Code
of Conduct and Ethics
|